High Quality Content by WIKIPEDIA articles! Radafaxine is drug candidate designated GW-353,162 by GlaxoSmithKline, investigated for treatment of restless leg syndrome and as an NDRI antidepressant. GlaxoSmithKline was targeting Radafaxine for regulatory filing in 2007, but development was discontinued in 2006 due to "poor test results".